We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
- Authors
Levin, Morris; Silberstein, Stephen D.; Gilbert, Robert; Lucas, Sylvia; Munsie, Leanne; Garrelts, Alyssa; Kennedy, Kate; Everman, Nicole; Pearlman, Eric
- Abstract
Background: The current study aimed to describe the impact of parental migraine on adolescent children (aged 11–17) living at home with a parent with migraine. Aim: Many drug classes are prescribed for migraine treatment, but all have limitations. Recently, calcitonin gene‐related peptide (CGRP) activity has shown a significant promise as a target for preventive therapy. In this review, we provide an overview of the potential role of CGRP mAbs in migraine, with a focus on their design, pharmacokinetics, safety, and immunogenicity. Conclusions: The CGRP mAbs are an innovative new therapy for migraine and address the need for effective and tolerable preventive options. MAbs, including those that target CGRP or its receptor, bind to a target with high specificity and affinity and lead to few off‐target adverse effects, although mechanism‐based adverse reactions may occur. Unlike other therapeutic antibodies used to treat neurologic disease, CGRP mAbs do not have a target within the immune system and have been designed to avoid altering the immune system. The safety and efficacy of mAbs against CGRP or its receptors are being investigated in clinical development programs, and the first of these therapies has received regulatory approval in the United States.
- Subjects
THERAPEUTIC use of monoclonal antibodies; CELL receptors; CALCITONIN; DRUG tolerance; MIGRAINE; MONOCLONAL antibodies; DRUG development; DRUG approval; THERAPEUTICS
- Publication
Headache: The Journal of Head & Face Pain, 2018, Vol 58, Issue 10, p1689
- ISSN
0017-8748
- Publication type
Article
- DOI
10.1111/head.13439